Clarithromycin-Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin's CYP induction. We found no differences in adverse events (10/13 vs 14/17; P = .73), drug intolerability (1/5 vs 4/11; P = 1), or 90-day mortality (0/13 vs 1/17; P = 1) in patients receiving clarithromycin vs azithromycin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 9(2022), 1 vom: 17. Jan., Seite ofab582 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gonzalez-Bocco, Isabel H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clarithromycin |
|---|
| Anmerkungen: |
Date Revised 08.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofab582 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335236162 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335236162 | ||
| 003 | DE-627 | ||
| 005 | 20231225225401.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofab582 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335236162 | ||
| 035 | |a (NLM)34988253 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gonzalez-Bocco, Isabel H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clarithromycin-Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin's CYP induction. We found no differences in adverse events (10/13 vs 14/17; P = .73), drug intolerability (1/5 vs 4/11; P = 1), or 90-day mortality (0/13 vs 1/17; P = 1) in patients receiving clarithromycin vs azithromycin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mycobacterium avium complex | |
| 650 | 4 | |a clarithromycin | |
| 650 | 4 | |a immunocompromised host | |
| 650 | 4 | |a nontuberculous mycobacteria | |
| 700 | 1 | |a Aleissa, Muneerah M |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Manne-Goehler, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Koo, Sophia |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Matthew P |e verfasserin |4 aut | |
| 700 | 1 | |a Marty, Francisco M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 9(2022), 1 vom: 17. Jan., Seite ofab582 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g number:1 |g day:17 |g month:01 |g pages:ofab582 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofab582 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |e 1 |b 17 |c 01 |h ofab582 | ||